187 related articles for article (PubMed ID: 1346716)
1. Sialyl-Tn, sialyl-Lewis Xi, CA 19-9, CA 125, carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumors.
Inoue M; Fujita M; Nakazawa A; Ogawa H; Tanizawa O
Obstet Gynecol; 1992 Mar; 79(3):434-40. PubMed ID: 1346716
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of serum sialyl Tn antigen in patients with gynecological cancer. STN Study Group].
Noda K; Shiota M; Tanizawa O; Inoue M; Tenjin Y; Sugishita T; Yakushiji M; Miyoshi T; Nozawa S; Sakuma T
Gan To Kagaku Ryoho; 1991 Jul; 18(8):1287-96. PubMed ID: 2069400
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity of monoclonal antibodies to carcinoembryonic antigen, tissue polypeptide antigen, alpha-fetoprotein, carbohydrate antigen 50, and carbohydrate antigen 19-9 in the diagnosis of colorectal adenocarcinoma.
Alvarez JA; Marín J; Jover JM; Fernández R; Fradejas J; Moreno M
Dis Colon Rectum; 1995 May; 38(5):535-42. PubMed ID: 7537651
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: relevance for differential diagnosis.
Tholander B; Taube A; Lindgren A; Sjöberg O; Stendahl U; Kiviranta A; Hallman K; Holm L; Weiner E; Tamsen L
Gynecol Oncol; 1990 Oct; 39(1):16-25. PubMed ID: 2227569
[TBL] [Abstract][Full Text] [Related]
5. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for sialyl TN antigen: (2). Evaluation of clinical significance. STN Study Group].
Imura H; Mori T; Ohkura H; Ishii M; Ariyoshi H; Endo J; Kitao M; Takeda I; Kobayashi H; Inoue M
Gan To Kagaku Ryoho; 1989 Sep; 16(9):3221-30. PubMed ID: 2571323
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of sialyl Tn antigen in patients with gynecologic tumors.
Inoue M; Ogawa H; Nakanishi K; Tanizawa O; Karino K; Endo J
Obstet Gynecol; 1990 Jun; 75(6):1032-6. PubMed ID: 2342728
[TBL] [Abstract][Full Text] [Related]
7. Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin.
Yabushita H; Sawaguchi K; Hieda S; Ogawa A; Tomatsu A; Noguchi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb; 41(2):217-24. PubMed ID: 2566639
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease.
Tholander B; Taube A; Lindgren A; Sjöberg O; Stendahl U; Tamsen L
Gynecol Oncol; 1990 Oct; 39(1):26-33. PubMed ID: 2227570
[TBL] [Abstract][Full Text] [Related]
9. Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and beta-chain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma.
Panza N; Pacilio G; Campanella L; Peluso G; Battista C; Amoriello A; Utech W; Vacca C; Lombardi G
Cancer; 1988 Jan; 61(1):76-83. PubMed ID: 2446734
[TBL] [Abstract][Full Text] [Related]
10. [Ovarian cancer--a comparison between CT diagnosis and serum tumor markers].
Wakabayashi Y; Yachida M; Akata S; Kawana K; Kotake F; Kakizaki D; Abe K; Negishi N; Akiya K
Gan No Rinsho; 1988 Jan; 34(1):52-6. PubMed ID: 3422324
[TBL] [Abstract][Full Text] [Related]
11. Tumor markers in the management of patients with ovarian cancer.
Tuxen MK; Sölétormos G; Dombernowsky P
Cancer Treat Rev; 1995 May; 21(3):215-45. PubMed ID: 7656266
[No Abstract] [Full Text] [Related]
12. Clinical usefulness of serum sialyl SSEA-1 antigen levels in patients with epithelial ovarian cancer. Comparative effectiveness of sialyl SSEA-1 and CA 125.
Kobayashi H; Kawashima Y
Gynecol Obstet Invest; 1990; 30(1):52-8. PubMed ID: 1977666
[TBL] [Abstract][Full Text] [Related]
13. [New prospects in the combined use of tumor markers in epithelial neoplasms of the ovary].
Indraccolo SR; Cecchi A; Thodos A; Brandi S; Carta G
Ann Ostet Ginecol Med Perinat; 1991; 112(1):36-40. PubMed ID: 1929097
[TBL] [Abstract][Full Text] [Related]
14. Expression of Tn and sialyl-Tn antigens in tumor tissues of the ovary.
Inoue M; Ton SM; Ogawa H; Tanizawa O
Am J Clin Pathol; 1991 Dec; 96(6):711-6. PubMed ID: 1720922
[TBL] [Abstract][Full Text] [Related]
15. Tn and sialyl-Tn antigens as potential prognostic markers in human ovarian carcinoma.
Ogawa H; Ghazizadeh M; Araki T
Gynecol Obstet Invest; 1996; 41(4):278-83. PubMed ID: 8793500
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal cancer follow-up: the effectiveness of sequential CEA, TPA and Ca 19-9 evaluation in the early diagnosis of recurrences.
Barillari P; Sammartino P; Cardi M; Ricci M; Gozzo P; Cesareo S; Cerasi A
Aust N Z J Surg; 1991 Sep; 61(9):675-80. PubMed ID: 1877936
[TBL] [Abstract][Full Text] [Related]
17. [Use of radioimmunoanalysis of tumor markers in the diagnosis of carcinoma of the breast, ovary and intestines].
Kausitz J
Bratisl Lek Listy; 1988 Aug; 89(8):563-76. PubMed ID: 3179762
[No Abstract] [Full Text] [Related]
18. Clinical evaluation of serum sialosyl-Tn antigen levels in comparison with CA 125 levels in gynecologic cancers.
Ryuko K; Iwanari O; Nakayama S; Iida K; Kitao M
Cancer; 1992 May; 69(9):2368-78. PubMed ID: 1562985
[TBL] [Abstract][Full Text] [Related]
19. Circulating sialyl Lewis(x), sialyl Lewis(a), and sialyl Tn antigens in colorectal cancer patients: multivariate analysis of predictive factors for serum antigen levels.
Nakagoe T; Sawai T; Tsuji T; Jibiki M; Nanashima A; Yamaguchi H; Kurosaki N; Yasutake T; Ayabe H
J Gastroenterol; 2001 Mar; 36(3):166-72. PubMed ID: 11291879
[TBL] [Abstract][Full Text] [Related]
20. Comparison between tissue and serum content of CA 125, CA 19-9, and carcinoembryonic antigen in ovarian tumors.
Breitenecker G; Neunteufel W; Bieglmayer C; Kölbl H; Schieder K
Int J Gynecol Pathol; 1989; 8(2):97-102. PubMed ID: 2714933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
